Next Phase Newsletter

A venture arm of a global advisory dedicated to healthcare with practices across regulatory and clinical affairs, market access and HEOR strategy consulting, and investment banking uses its experience in the industry to invest in promising early stage companies developing medical devices, diagnostics or digital health technologies. The firm invests at the seed stage, and serves as a strategic investor as much as a financial investor, using industry knowledge and contacts to help companies grow. The firm will generally invest between $250K-1M in companies that have some proof of concept and IP. The firm will invest globally.

The firm invests in medical device, diagnostics and digital health companies. While the firm is generally agnostic to subsector and indication, it tends to avoid companies with a long time to exit. In addition, while the firm is willing to consider all types of medical devices, they are less likely to invest in PMA devices at this stage.

The firm is a very active investor, and thus takes a board seat, even if just an observer position, to lend their expertise. The firm can lead or coinvest, but tends to coinvest, and can help build a syndicate with their contacts.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund based in USA leads investments in high growth, mostly US-based Healthcare IT, SaaS, PaaS and technology-enabled service businesses. The firm has a flexible model to right-size equity investments with initial investments typically around $10M. The firm is active in governance and seeks to remain involved through multiple financing rounds. The fund targets a 5-year investment window.

The fund investments are focused on a few key themes in businesses that improve the human condition and deliver value-based care.  It seeks investments in B2B or B2B2C companies with proven business models and experienced teams pursuing end-market opportunities large enough to support creation of companies with $1B in enterprise value. Thematic areas of focus include personalized medicine, patient navigation, referral management, and enablement of payer-provider risk sharing.

The firm is open to work with management teams with various levels of experience. The fund does seek a board seat along with investment and prefers to be fairly involved with the management team and strategy of the company. The fund does not purchase secondary shares of a company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of an investment firm founded by a family office in Hong Kong is focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and more. The firm is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.

The firm seeks to invest in new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc. For therapeutics, the firm seeks novel small molecule and biologics and is agnostic in terms of indication. However, indications that address a large market in China are of interest. The firm looks for early stage assets in pre-clinical and phase I of clinical trials. However, the firm will not rule out assets in phase II. For devices, the firm is opportunistic in terms of the class of device.

The firm seeks an active role in its portfolio companies and generally obtain a seat on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in the USA closed its first fund in 2017 and is actively seeking new investment opportunities. The fund will make 15-20 investments in total with no set number of investments per year. The firm will be actively involved in their portfolio companies and will invest up to $25 million over the life of each portfolio company. Initial check sizes will depend on the company’s stage of development and their needs prior to investment. The firm will invest in North American or European companies.

The firm is focused solely on therapeutics and therapeutic platforms. The fund will invest at any stage of development from preclinical / discovery stage through Phase 3 clinical, and will invest in all therapeutic areas.

The firm can work with companies at all stages of their evolution. The firm’s team has the capability and experience to build companies from the ground up, however generally gets involved with at least the beginnings of a management team in place. The firm can both lead and co-invest along syndicates and will generally seek board representation in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Canada will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital.

The firm has a general theme of investing in technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital company based in USA manages just under $70 million in assets across 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States  and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm based in USA makes co-investments into early stage life science companies.  The firm prefers to invest in Series A-B rounds, and does not make seed investments.  The firm makes investments of up to $300,000 out of the firm’s own capital, and is also working with an international partner that makes investments of up to $30 million in medical devices. The firm invests in startups US-wide.

The firm invests broadly in the life sciences and will consider opportunities in therapeutics, devices, diagnostics, healthcare IT and life science tools. The firm’s partner org is focused on late stage opportunities in the electronic medical device sector and will invest up to $30 million in these opportunities, with an interest in opportunities in which this org can act as a manufacturing partner.  In other sectors, the firm makes early stage investments in companies that have established proof of concept, and interests include  orphan drugs, the microbiome, healthcare data science, tools and some devices.

The firm prefers to invest in companies that have already received a significant round of funding in the past.  For data and healthcare IT companies, initial revenues are preferred.  The firm focuses on opportunities that will provide a short path to exit. The firm takes an active role with portfolio companies, particularly in making strategic and market connections with partners in Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.